Compare TWIN & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TWIN | TVGN |
|---|---|---|
| Founded | 1918 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Blank Checks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 21.3M |
| IPO Year | 1994 | 2021 |
| Metric | TWIN | TVGN |
|---|---|---|
| Price | $24.98 | $6.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 55.1K | 7.0K |
| Earning Date | 11-04-2026 | 11-24-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | ★ 1428.57 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $381,270,000.00 | N/A |
| Revenue This Year | $7.56 | N/A |
| Revenue Next Year | $8.00 | N/A |
| P/E Ratio | $101.54 | ★ N/A |
| Revenue Growth | ★ 11.90 | N/A |
| 52 Week Low | $14.22 | $0.14 |
| 52 Week High | $29.24 | $24.91 |
| Indicator | TWIN | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 46.06 |
| Support Level | $22.10 | $4.14 |
| Resistance Level | $27.58 | $7.33 |
| Average True Range (ATR) | 1.37 | 0.45 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 50.19 | 49.75 |
Twin Disc Inc designs, manufactures and sells marine and heavy-duty off highway power transmission equipment. Its products are marine transmissions, azimuth drives, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, controls systems, and braking systems. The company sells its products to customers in the pleasure craft, commercial, and military marine markets, as well as in the energy and natural resources, government, military, and industrial markets. It has two reportable segments: manufacturing and distribution. It derives the maximum revenue from the manufacturing segment. Geographically, it operates in United States, Netherlands, Finland, China, Australia, Italy and Others.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.